Oncology Institute, Inc. (TOI): Nasdaq/NYSE listing notice — Nasdaq grants TOI additional 180 days to meet $1 minimum bid price through June 16, 2025

Oncology Institute, Inc.

Received Second Nasdaq Bid Price Letter on Dec 19, 2024 granting extension to June 16, 2025.
Company must regain compliance with minimum $1.00 bid price by end of Second Compliance Period.
May consider a reverse stock split to cure deficiency; split must be completed 10 business days before deadline.
If compliance not met, Nasdaq will issue delisting notice; Company may appeal to Nasdaq Hearings Panel.
No immediate effect on listing or trading of common stock (TOI) or warrants (TOIIW).

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Oncology Institute, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 19, 2024 (the “Second Nasdaq Bid Price Letter”), Nasdaq notified the Company that Nasdaq’s Staff has determined that the Company is eligible for an additional 180 calendar day period, or until June 16, 2025, to regain compliance (the “Second Compliance Period”). The determination is based on the Company’s meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company’s written notice of its intention to cure

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-24-001742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.